The global sepsis diagnostics market is experiencing significant growth, driven by the increasing prevalence of sepsis, a life-threatening condition caused by the body's response to an infection. The rise in hospital-acquired infections and the growing elderly population, who are more susceptible to infections, are key factors contributing to this market expansion. Additionally, the emphasis on early detection and treatment of sepsis to improve patient outcomes is fueling the demand for advanced diagnostic tools and techniques. The market is characterized by a range of diagnostic methods, including blood culture tests, molecular diagnostics, immunoassays, and biomarkers. These technologies offer rapid and accurate identification of pathogens, aiding in timely and effective treatment decisions. Major players in the market are focusing on strategic initiatives such as product launches, collaborations, and acquisitions to strengthen their market presence and expand their product offerings.
Data Bridge Market Research analyses that the Sepsis Diagnostics Market is growing with a CAGR of 8.0% in the forecast period of 2022 to 2029.
To know more, visit https://www.databridgemarketresearch.com/jp/reports/global-sepsis-diagnostics-market
Below are the Top Five Sepsis Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
Roche offers a range of innovative products and solutions. The company's diagnostics division develops and manufactures diagnostic tests and systems for the early detection, diagnosis, and monitoring of sepsis. Roche's commitment to advancing healthcare through cutting-edge technology and research has solidified its position as a key player in the market.
|
|
Americas, Middle East and Africa, Europe, Asia- Pacific
|
In June 2016, Roche diagnostics has received FDA 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay, which is a dedicated solution for people with severe sepsis or septic shock. This product made Roche the first IVD company in U.S. to provide an integrated solution for sepsis management. Thereby, this approval enhanced its foothold in the market.
|
|
2.
|
Abbott
|
Abbott is known for its innovative diagnostic solutions. The company offers a comprehensive portfolio of diagnostic tests and systems for sepsis detection and monitoring. Abbott's dedication to improving patient outcomes and advancing healthcare has made it a trusted name in the field of sepsis diagnostics.
|
|
Asia, Greater China, Europe, Middle East and Africa, The Americas
|
In June 2017, Abbott launches Point-of-care sensors that provided diagnosis of sepsis as it is a life-threatening organ dysfunction caused by a dysregulated host response to infection. This launch was a great help to the patients as well as earned a good revenue to the company.
|
|
3.
|
BIOMÉRIEUX
|
BIOMÉRIEUX is a prominent player in the global sepsis diagnostics market, offering a wide range of diagnostic tests and systems for the rapid and accurate detection of sepsis-causing pathogens. The company's commitment to innovation and quality has earned it a strong reputation among healthcare professionals worldwide.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In November 2016, bioMérieux announced that it has received market clearance from the U.S. Food and Drug Administration (FDA) for the VIDAS B•R•A•H•M•S PCT for the direct detection of bacterial species in human whole blood. This launch helped the company to increase its revenue.
|
|
4.
|
Thermo Fisher Scientific Inc.
|
Thermo Fisher Scientific Inc. provides innovative diagnostic solutions for the early detection and monitoring of sepsis. The company's diagnostic tests and systems are known for their accuracy, reliability, and ease of use, making them a preferred choice among healthcare professionals.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In January 2021, Thermo Fisher Scientific Inc. announced its definitive agreement to acquire Mesa Biotech, Inc., for the enhancement of Sepsis Diagnostics services.
The acquisition helped the company to grow its product portfolio.
|
|
5.
|
BD
|
BD offers a range of diagnostic tests and systems for the rapid and accurate detection of sepsis-causing pathogens. The company's commitment to innovation and quality has made it a trusted partner for healthcare providers worldwide in the fight against sepsis.
|
|
North America, Middle East and Africa, Europe, South America, Asia- Pacific
|
In March 2019, BD launched a new automated flow cytometry sample preparation instrument called BD FACSDuet with CE-IVD Certification. This instrument used in the laboratory for diagnosis purposes with less errors. This launch has helped company to increase its revenue and grow the global presence.
|
Conclusion
The global sepsis diagnostics market is experiencing significant growth, driven by factors such as the increasing prevalence of sepsis, the rise in hospital-acquired infections, and the growing elderly population. Key players in the market, including F. Hoffmann-La Roche Ltd., Abbott, BIOMÉRIEUX, Thermo Fisher Scientific Inc., and BD, are focusing on innovation to develop advanced diagnostic tools and techniques for early detection and treatment of sepsis. These companies have a strong global presence and offer a wide range of products, including blood culture systems, molecular diagnostics, and immunoassays, to cater to the diverse needs of healthcare facilities worldwide.
